All posts

Jushi has target slashed by Beacon Securities

The stock is still a “Buy” but Beacon Securities analyst Russell Stanley has dimmed his outlook for US cannabis company Jushi Holdings (Jushi Stock Quote, Charts, News, Analysts, Financials CSE:JUSH). In a Thursday report to clients, Stanley lowered his target price from C$7.00 to C$3.50 per share, saying Jushi’s potential in the state of Virginia is worth watching.

Multi-state cannabis company Jushi, which has core markets in Illinois, Pennsylvania and Virginia and additional interests in California, Nevada, Ohio and Massachusetts, announced on Thursday that it has refinanced its debt otherwise due to mature next month and it also modified its other major debt facility to reduce covenant requirements. Proceeds from the $69 million debt financing will go with the company’s $9 million cash on hand to repay the company’s ten per cent senior secured notes. Jushi issued 16 million warrants convertible at C$2.84 per share, expiring December 2026.

With the new financing, Jushi’s forward earnings took a hit in Stanley’s estimates, where his 2023 adjusted EBITDA forecast has now been reduced from $138 million to $75 million, resulting in the drop in the analyst’s target price.

“We continue to view JUSH as one of the most revenue-levered plays on Virginia (still our #1 draft pick amongst cannabis markets, expected to open the adult-use market in January 2024) and Pennsylvania (likely to revisit AU legalization during the 2023 legislative session),” Stanley wrote.

Looking at the upcoming fourth quarter results, Stanley noted that in the company’s third quarter report in November management had reiterated its previous guidance for annualized revenue of $320-$350 million, with low double-digit EBITDA margins. Stanley said that translates to about $84 million and $10 million in revenue and adjusted EBITDA, respectively. For his part, Stanley is forecasting $79 million and $4 million. Further afield and with the new amendment, the analyst’s call is for 2023 revenue and adjusted EBITDA of $404 million and $75 million, respectively.

“JUSH is trading at 8.9x our new F2023 adjusted EBITDA forecast, representing a nine per cent premium to the 8.2x average amongst US operators. Potential catalysts include additional retail openings (particularly in VA), other buildout updates and the Q4 results in early 2023,” he said.

US pot stocks sold off sharply in recent sessions, with Stanley pointing to the exclusion of the SAFE Banking Act from the US National Defense Authorization Act as a factor. For Jushi, the development has taken the stock into a test of its original uptrend, Stanley said, as well as its 50-day moving average, which could offer near-term support, he says. At press time, Stanley’s new C$3.50 target represented a projected one-year return of 51 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: jush
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago